Cystatin C in cerebrospinal fluid as a biomarker of ALS

Neuroscience Letters

Volumn 452, Issue 1, 2009, Pages 52-55

  Tsuji Akimoto, Sachiko ^a   Yabe, Ichiro ^a   Niino, Masaaki ^a   Kikuchi, Seiji ^b   Sasaki, Hidenao ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HOKKAIDO MEDICAL CENTER   (Japan)

Author keywords

Amyotrophic lateral sclerosis; Biomarker; Cystatin C; Diagnosis

Indexed keywords

BIOLOGICAL MARKER; CYSTATIN C;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MEASUREMENT; MOTONEURON; NEUROLOGIC DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; CYSTATIN C; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVOUS SYSTEM DISEASES; POLYNEUROPATHIES;

EID: 59349116480     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.01.026     Document Type: Article

References (36)

1. Abrahamson M., Barrett A.J., Salvesen G., and Grubb A. Isolation of six cysteine proteinase inhibitors from human urine. Their physicochemical and enzyme kinetic properties and concentrations in biological fluids. J. Biol. Chem. 261 (1986) 11282-11289
2. Abrahamson M., Olafsson I., Palsdottir A., Ulvsback M., Lundwall A., Jensson O., and Grubb A. Structure and expression of the human cystatin C gene. Biochem. J. 268 (1990) 287-294
3. Beghi E., Millul A., Micheli A., Vitelli E., Logroscino G., and Group SLALOM. Incidence of ALS in Lombardy, Italy. Neurology 68 (2007) 141-145
4. Bjarnadottir M., Nilsson C., Lindström V., Westman A., Davidsson P., Thormodsson F., Blöndal H., Gudmundsson G., and Grubb A. The cerebral hemorrhage-producing cystatin C variant (L68Q) in extracellular fluids. Amyloid 8 (2001) 1-10
5. Bjarnadottir M., Wulff B.S., Sameni M., Sloane B.F., Keppler D., Grubb A., and Abrahamson M. Intracellular accumulation of the amyloidogenic L68Q variant of human cystatin C in NIH/3T3 cells. Mol. Pathol. 51 (1998) 317-326
6. Brooks B.R. Diagnostic dilemmas in amyotrophic lateral sclerosis. J. Neurol. Sci. 165 Suppl. 1 (1999) S1-S9
7. Brooks B.R., Miller R.G., Swash M., and Munsat T.L. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Motor Neuron Disord. 1 (2000) 293-299
8. Cudkowicz M.E., Shefner J.M., Schoenfeld D.A., Zhang H., Andreasson K.I., Rothstein J.D., and Drachman D.B. Trial of celecoxib in amyotrophic lateral sclerosis. Ann. Neurol. 60 (2006) 22-31
9. Davenport R., Swingler R., Chancellor A., and Warlow C. Avoiding false positive diagnoses of motor neuron disease: lessons from the Scottish Motor Neuron Disease Register. J. Neurol. Neurosurg. Psychiatry 60 (1996) 147-151
10. Del Boccio P., Pieragostino D., Lugaresi A., Di Ioia M., Pavone B., Travaglini D., D'Aguanno S., Bernardini S., Sacchetta P., Federici G., Di Ilio C., Gambi D., and Urbani A. Cleavage of cystatin C is not associated with multiple sclerosis. Ann. Neurol. 62 (2007) 201-204 discussion 205
11. Gordon P.H., Moore D.H., Miller R.G., Florence J.M., Verheijde J.L., Doorish C., Hilton J.F., Spitalny G.M., MacArthur R.B., Mitsumoto H., Neville H.E., Boylan K., Mozaffar T., Belsh J.M., Ravits J., Bedlack R.S., Graves M.C., McCluskey L.F., Barohn R.J., and Tandan R. Western ALS Study Group, Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6 (2007) 1045-1053
12. Grubb A., Jensson O., Gudmundsson G., Arnason A., Lofberg H., and Malm J. Abnormal metabolism of gamma-trace alkaline microprotein. The basic defect in hereditary cerebral hemorrhage with amyloidosis. N. Engl. J. Med. 311 (1984) 1547-1549
13. Hansson S.F., Simonsen A.H., Zetterberg H., Andersen O., Haghighi S., Fagerberg I., Andreasson U., Westman-Brinkmalm A., Wallin A., Ruetschi U., and Blennow K. Cystatin C in cerebrospinal fluid and multiple sclerosis. Ann. Neurol. 62 (2007) 193-196 discussion 205
14. Ishiguro H., Ohkubo I., Mizokami M., Titani K., and Sasaki M. The use of monoclonal antibodies to define levels of cystatin C in normal human serum. Hybridoma 8 (1989) 303-313
15. Janowski R., Kozak M., Jankowska E., Grzonka Z., Grubb A., Abrahamson M., and Jaskolski M. Human cystatin C, an amyloidogenic protein, dimerizes through three-dimensional domain swapping. Nat. Struct. Biol. 8 (2001) 316-320
16. Liu X.D., Zeng B.F., Xu J.G., Zhu H.B., and Xia Q.C. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 6 (2006) 1019-1028
17. Lofberg H., and Grubb A.O. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system. Scand. J. Clin. Lab. Invest. 39 (1979) 619-626
18. Makki A.A., and Benatar M. The electromyographic diagnosis of amyotrophic lateral sclerosis: does the evidence support the El Escorial criteria?. Muscle Nerve 35 (2007) 614-619
19. Mizuno Y., Amari M., Takatama M., Aizawa H., Mihara B., and Okamoto K. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol. 112 (2006) 597-603
20. Nakashima I., Fujinoki M., Fujihara K., Kawamura T., Nishimura T., Nakamura M., and Itoyama Y. Alteration of cystatin C in the cerebrospinal fluid of multiple sclerosis. Ann. Neurol. 62 (2007) 197-200 discussion 205
21. Okamoto K., Hirai S., Amari M., Watanabe M., and Sakurai A. Bunina bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. Neurosci. Lett. 162 (1993) 125-128
22. Olafsson I., Thorsteinsson L., and Jensson O. The molecular pathology of hereditary cystatin C amyloid angiopathy causing brain hemorrhage. Brain Pathol. 6 (1996) 121-126
23. O'Toole O., Traynor B.J., Brennnan P., Sheehan C., Frost E., Corr B., and Hardiman O. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J. Neurol. Neurosurg. Psychiatry 79 (2008) 30-32
24. Palsdottir A., Abrahamson M., Thorsteinsson L., Arnason A., Olafsson I., Grubb A., and Jensson O. Mutation in cystatin C gene causes hereditary brain haemorrhage. Lancet 2 (1988) 603-604
25. Pasinetti G.M., Ungar L.H., Lange D.J., Yemul S., Deng H., Yuan X., Brown R.H., Cudkowicz M.E., Newhall K., Peskind E., Marcus S., and Ho L. Identification of potential CSF biomarkers in ALS. Neurology 66 (2006) 1218-1222
26. Ranganathan S., Williams E., Ganchev P., Gopalakrishnan V., Lacomis D., Urbinelli L., Newhall K., Cudkowicz M.E., Brown Jr. R.H., and Bowser R. Proteomic profiling of cerebrospinal fluid identifies biomarkers for amyotrophic lateral sclerosis. J. Neurochem. 95 (2005) 1461-1471
27. Reed C.H. Diagnostic applications of cystatin C. Br. J. Biomed. Sci. 57 (2000) 323-329
28. Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O'Regan J.P., Deng H.X., Rahmani Z., Krizus A., McKenna-Yasek D., Cayabyab A., Gaston S.M., Berger R., Tanzi R.E., Halperin J.J., Herzfeldt B., Van den Bergh R., Hung W.Y., Bird T., Deng G., Mulder D.W., Smyth C., Laing N.G., Soriano E., Pericak-Vance M.A., Haines J., Rouleau G.A., Gusella J.S., Horvitz H.R., and Brown R.H. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
29. Ruetschi U., Zetterberg H., Podust V.N., Gottfries J., Li S., Hviid Simonsen A., McGuire J., Karlsson M., Rymo L., Davies H., Minthon L., and Blennow K. Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF. Exp. Neurol. 196 (2005) 273-281
30. Sanchez J.C., Guillaume E., Lescuyer P., Allard L., Carrette O., Scherl A., Burgess J., Corthals G.L., Burkhard P.R., and Hochstrasser D.F. Cystatin C as a potential cerebrospinal fluid marker for the diagnosis of Creutzfeldt-Jakob disease. Proteomics 4 (2004) 2229-2233
31. Shefner J.M., Cudkowicz M.E., Schoenfeld D., Conrad T., Taft J., Chilton M., Urbinelli L., Qureshi M., Zhang H., Pestronk A., Caress J., Donofrio P., Sorenson E., Bradley W., Lomen-Hoerth C., Pioro E., Rezania K., Ross M., Pascuzzi R., Heiman-Patterson T., Tandan R., Mitsumoto H., Rothstein J., Smith-Palmer T., MacDonald D., and Burke D. NEALS Consortium, A clinical trial of creatine in ALS. Neurology 63 (2004) 1656-1661
32. Swash M. Learning from failed trials in ALS. Lancet Neurol. 6 (2007) 1034-1035
33. Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., and Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch. Neurol. 57 (2000) 109-113
34. Traynor B.J., Codd M.B., Corr B., Forde C., Frost E., and Hardiman O.M. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch. Neurol. 57 (2000) 1171-1176
35. Wakabayashi K., Yoshimoto M., Tsuji S., and Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci. Lett. 249 (1998) 180-182
36. Zoccolella S., Beghi E., Palagano G., Fraddosio A., Samarelli V., Lamberti P., Lepore V., Serlenga L., and Logroscino G. SLAP registry, signs and symptoms at diagnosis of amyotrophic lateral sclerosis: a population-based study in southern Italy. Eur. J. Neurol. 13 (2006) 789-792